Anti-TROP2 (Sacituzumab Govitecan), Humanized Antibody

Anti-TROP2 (Sacituzumab Govitecan), Humanized Antibodyis available at Gentaur for Next week Delivery.

Description: The research-grade biosimilar is an antibody-drug conjugate that targets TROP-2 that is expressed on cancer cells. The original conjugate consists of an anti-TROP2 humanized monoclonal antibody (RS7-3G11) that is chemically linked to a cytotoxic drug SN-38 via a hydrolyzable CL2A linker. Upon internalization in the cell, the SN-38 is released from the antibody via the hydrolysis of the CL2A linker. SN-38 inhibits DNA topoisomerase I and induces DNA-damage mediated cell death. The original antibody-drug conjugate received approval from the FDA in 2020 to treat patients with metastatic triple-negative breast cancer who have received at least two prior treatment regimens

Immunogen Sequence:Human TROP2

Target Alternative Name:IMMU-132, hRS7-SN-38, hRS7-SN-38-ADC, hRS7-[CL-SN-38], hRS 7SN38, hRS7-SN38, IMMU 132, EGP1, GP50, M1S1, EGP-1, TACSTD2, GA7331, GA733-1

Species Reactivities:Human

Tag Line:The biosimilar is an antibody-drug conjugate that targets cancer cells expressing TROP-2 and induces cell death via DNA damage. The original antibody-drug conjugate is approved to treat metastatic breast cancer

Formulation:In PBS, pH 7.5

Purification: Protein A purified

Application:/

Positive Control:/

Application And Usages:/

Handling:The antibody solution should be gently mixed before use.